by admin | Nov 25, 2019 | FDA
Usona Institute has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for psilocybin in the treatmentof major depressive disorder (MDD). Breakthrough Therapy Designation establishes FDA’s organizational commitment to promoting an...
by admin | Nov 25, 2019 | Funding
Azeria Therapeutics, a newly formed pioneer factor drug discovery company, announced a £32 million Series B financing in which Syncona has committed £29.5 million alongside existing investor the CRT Pioneer Fund. Azeria was originally founded in 2017 by Sixth Element...
by admin | Nov 25, 2019 | CE mark
AiVoni Analysis Service by Heart2Save from Finland determines four different arrhythmias, allowing especially detection of atrial fibrillation. Early detection of arrhythmia significantly reduces the number of strokes caused by atrial fibrillation and thus saves lives...
